Bearish Perspectives on Pharma Amid Economic Turmoil

This chapter examines HSBC's negative perspective on the pharmaceutical sector, influenced by U.S. tariffs, a looming patent cliff, and the implications of the Inflation Reduction Act. It further explores the impact of these challenges on key companies like Novartis and Eli Lilly as they approach their earnings reports, while discussing market uncertainties and trading strategies.